Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-6914 in advanced prostate cancer
NCT07735377Phase 1Recruiting
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Aug 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SHR-6914 in prostate cancer (PCa), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 6 months, Adverse Events at 6 months and 3 more. Started Aug 2026; status: recruiting.
02
Drugs
SHR-6914
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07735377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07735377.